Core Viewpoint - The rise of male consumers, particularly those born in the 1990s, is significantly impacting the medical beauty market in China, driven by changing perceptions of masculinity and beauty standards [2][5][10]. Group 1: Market Trends - The medical beauty market in China is experiencing a shift, with a notable increase in male users, particularly among those born in the 1990s, who are now seen as a key demographic for growth [2][9]. - In the past year, the percentage of male customers visiting medical beauty institutions has risen from 4.9% to 7.3%, indicating a growing acceptance and demand for medical beauty services among men [2][3]. - The average spending per male customer is approximately 2.75 times higher than that of female customers, highlighting the potential profitability of targeting male consumers [10][11]. Group 2: Consumer Behavior - Male consumers, especially those in their 20s to 40s, prefer subtle and natural-looking enhancements, with a focus on skin care and anti-aging treatments rather than more invasive procedures [3][6]. - The primary motivations for male medical beauty users include improving personal image for career and dating prospects, rather than purely aesthetic reasons [6][8]. - Social media has played a crucial role in shaping the beauty standards and consumption habits of younger male consumers, who are more open to exploring medical beauty options [7][9]. Group 3: Industry Challenges - Despite the growing market, the medical beauty industry faces challenges such as a lack of trust and awareness among potential male consumers, which hinders market penetration [9][12]. - The industry is also grappling with rising costs of materials and new regulations that impact marketing strategies, making it essential for brands to find innovative ways to attract male customers [9][10]. - Education and awareness campaigns are necessary to inform male consumers about available treatments and to alleviate any stigma associated with medical beauty procedures [12][16]. Group 4: Future Outlook - The male medical beauty market is expected to grow significantly, with projections indicating that by 2025, the market size could exceed 500 billion yuan, with male consumers accounting for over 30% of the market [9][16]. - The next three to five years are seen as a critical window for the male medical beauty sector to expand, with potential for tailored services and products designed specifically for male consumers [16]. - As the market matures, there will likely be a diversification of services, including specialized offerings in hair restoration and body sculpting, catering to the unique needs of male clients [15][16].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [6][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.05% from June 13 to June 26, 2025, which is approximately 6.43 percentage points lower than the index [13][26]. - All sub-sectors within the industry recorded negative returns during the same period, with medical consumables and hospital sectors experiencing the least decline at 0.17% and 0.4%, respectively. In contrast, chemical preparations and offline pharmacy sectors saw larger declines of 6.12% and 6.11% [14][26]. - Approximately 16% of stocks in the industry recorded positive returns, while around 84% experienced negative returns during the reporting period [15][18]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 47.76 times as of June 26, 2025, which is 3.83 times relative to the CSI 300 index. The industry valuation has decreased and is currently at a relatively low level compared to recent years [19][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 5.05% from June 13 to June 26, 2025 [13]. - All sub-sectors recorded negative returns, with the least affected being medical consumables and hospitals [14]. - About 16% of stocks in the industry had positive returns, with the highest gainers and losers identified [15][18]. 2. Industry News - The report highlights significant developments in the industry, including the implementation of centralized procurement for traditional Chinese medicine across 25 provinces, set to take effect from July 1, 2025 [24]. 3. Company Announcements - Notable announcements include a licensing agreement by Rongchang Biopharmaceuticals, which will receive $125 million in cash and potential milestone payments up to $4.105 billion from Vor Biopharma for the development and commercialization of a product [25]. 4. Weekly Industry Perspective - The report suggests continued focus on investment opportunities within the innovative drug sector, particularly as domestic companies begin to reap the benefits of years of research and development [26][28].

Core Insights - The 67th China (Shanghai) International Beauty Expo successfully showcased the vitality and potential of the beauty industry, emphasizing resilience, innovation, and intelligence in development [1][2] Group 1: Event Overview - The expo covered an exhibition area of 150,000 square meters, featuring over 1,800 exhibitors from more than 68 countries and regions, displaying over 10,000 selected product categories [2] - The event attracted significant foot traffic and facilitated vibrant business exchanges, highlighting the robust market activity within the beauty sector [2] Group 2: Global Expansion - The expo aimed to build a new ecosystem for diverse cooperation in the beauty industry, establishing an efficient global communication platform for sourcing and sales [3] - It gathered professional buyers from various channels, including traditional retailers and new e-commerce trends, showcasing international exhibitors from countries like South Korea, Japan, the USA, and Canada [3] - Plans for 2025 include the addition of the "Indonesia International Beauty Expo" and "Vietnam International Beauty Expo," supporting Chinese beauty brands in expanding overseas [3] Group 3: Industry Innovation - The expo focused on industry logic, uniting upstream and downstream brand forces, with new products covering multiple fields, enhancing brand competitiveness and driving technological upgrades [4] - AI technology in beauty attracted attention, while several medical beauty brands accelerated their entry into the daily skincare market [4] - The event highlighted the "Matthew Effect" in the daily chemical sector, with leading brands leveraging resources to enter professional channels [4] Group 4: Future Trends - The expo outlined a development blueprint for the beauty industry through a systematic approach of summits, activities, and special exhibitions, providing forward-looking insights [5] - Over 50 special events were held during the expo, covering topics such as beauty, health, and e-commerce, enhancing the industry's outreach and impact [5] - The event featured 15+ themed exhibition areas, showcasing innovations in professional technology, AI applications, and cross-industry segments [5] Group 5: Looking Ahead - The beauty expo is set to embark on a new journey, focusing on domestic demand and actively exploring new growth areas for Chinese beauty brands [6] - The next edition, the 68th China (Guangzhou) International Beauty Expo, is scheduled for September 4-6, 2025, in Guangzhou [6]

Core Viewpoint - The article highlights a shift in investment strategies among leading public funds in June, indicating a transition towards value-oriented and low-valuation themes in response to changing market conditions [1][2][11]. Group 1: New Product Launch Strategies - Major public funds such as GF Fund, Fuguo Fund, and Huatai-PB Fund launched new balanced theme funds focused on value and low valuation in late June [2][4]. - The cautious approach in building positions for new funds, such as the Ping An Value Enjoyment Mixed Fund, reflects a strategy to navigate the current market volatility [4][5]. - The emergence of terms like "valuation advantage" and "balanced strategy" in new fund names suggests a growing emphasis on performance expectations for mid-term financial results [7][11]. Group 2: Market Trends and Performance Expectations - The article notes a significant cooling in the innovative pharmaceutical sector, with many companies experiencing rapid valuation increases that may not be sustainable [8][11]. - As the market approaches mid-2025, there is a shift in focus towards low-valuation companies that have shown performance improvement trends, making them attractive for institutional investors [8][11]. - The performance of stocks like Shangmei Co., which saw a 74% increase in net profit for 2024, illustrates the connection between market movements and mid-term financial expectations [8]. Group 3: Rebalancing Strategies and Future Outlook - The rebalancing of fund holdings indicates a potential influx of capital into low-valuation sectors, particularly in the Hong Kong non-bank sector, which currently has a PB of 0.98X and a dividend yield of 3.2% [12]. - The article suggests that the current market trend is moving away from thematic investments towards larger-cap stocks, with a preference for value stocks over growth stocks [11][12]. - The anticipated policy trading in early July may further influence market dynamics, with larger-cap stocks expected to exhibit greater elasticity compared to smaller-cap stocks [12].

Group 1: Industry Trends - The concept of "anti-aging" is evolving towards a holistic and root-cause approach, integrating beauty and health, which presents a new development direction for the Chinese medical aesthetics industry [1] - The medical aesthetics industry is transitioning from focusing on superficial beauty to addressing deeper health needs, particularly in the context of women's health and ovarian rejuvenation [2][3] Group 2: Women's Awareness and Market Demand - Women's awareness of anti-aging has undergone significant changes, shifting from a focus on external beauty to internal health, particularly regarding ovarian health [2][3] - A report indicates that 98% of respondents consider ovarian aging a core issue in anti-aging discussions, highlighting a growing market demand for solutions targeting ovarian health [2][3] Group 3: Product and Solution Development - RETRUEGEN, a product aimed at improving ovarian function, utilizes a unique mechanism that promotes cell survival and reduces apoptosis, showing significant clinical improvements in hormone levels and menstrual health [5] - The product is the only NMPA-approved intravenous human placenta product, which enhances its efficacy and safety profile, achieving nearly 100% bioavailability [5] Group 4: Market Opportunities and Growth - The introduction of RETRUEGEN opens new market opportunities by bridging the gap between medical aesthetics and health, addressing the saturation of traditional facial anti-aging products [6][7] - The global women's health market is projected to reach nearly $100 billion by 2030, with significant growth potential in China, where awareness of ovarian health is still developing [6][7] Group 5: Business Model and Competitive Advantage - RETRUEGEN's approach allows medical aesthetics institutions to meet the evolving demands of high-net-worth clients, moving beyond traditional facial treatments to comprehensive ovarian health solutions [7] - The product's model encourages a low-entry point for clients while fostering high repeat purchase rates, helping institutions break free from the cycle of customer acquisition and attrition [7]

Core Viewpoint - The medical beauty industry in China is experiencing rapid growth and transformation, driven by digitalization and AI technologies, aiming to enhance service quality and consumer trust [1][2][3]. Group 1: Industry Growth and Trends - The medical beauty industry has grown at an annual rate of 17%-22% over the past decade, but there are challenges related to consumer decision-making and trust due to uneven service quality across regions [2][3]. - The top ten cities in China account for over 50% of the total number of medical beauty doctors, indicating a significant regional disparity in service quality [2]. Group 2: Company Innovations and Strategies - The company, New Oxygen, has pioneered the application of digital technologies in the medical beauty sector, establishing the first medical beauty e-commerce platform in China in 2013 to address information asymmetry [3]. - New Oxygen has transitioned to a physical presence by opening its first light medical beauty chain store in May 2023, aiming to create a trustworthy service model through digital and standardized management [3][4]. - The company is developing a fully digital "smart clinic" solution that integrates AI-assisted diagnosis and treatment processes, enhancing service efficiency and quality [4][5]. Group 3: Future Vision and Expansion - New Oxygen envisions future stores as "smart stores" and aims to establish the first "data-algorithm-service" closed loop in the medical beauty industry, having opened 31 stores across nine cities in two years, making it the largest light medical beauty chain in China [5].

Core Viewpoint - The article highlights the risks associated with the "private label hyaluronic acid" model in the medical aesthetics industry, where legitimate products are used for marketing while unregulated or low-quality products are injected into consumers, leading to potential health hazards [1][3][40]. Group 1: Market Dynamics - The "private label hyaluronic acid" has gained popularity due to its high profit margins, with some products showing a price difference of over 10 times from production to retail [4][18]. - The medical aesthetics market is experiencing a surge in demand for hyaluronic acid, which is widely used for cosmetic procedures, creating a lucrative environment for private label products [5][12]. - As of 2024, there are approximately 70 active medical-grade hyaluronic acid products in the market, with intense competition among manufacturers [12]. Group 2: Regulatory Environment - The production of medical-grade hyaluronic acid requires strict regulatory compliance, and currently, only 15 domestic companies have the necessary production qualifications in China [8][10]. - The phenomenon of "one certificate, multiple brands" allows manufacturers to produce various products under a single medical device registration, creating a loophole for private label products [10][11]. - Recent regulations from the National Medical Products Administration have prohibited the commission of production for high-risk products, including hyaluronic acid, indicating a tightening of oversight in the industry [35][36]. Group 3: Consumer Risks - The influx of unregulated or poorly manufactured hyaluronic acid products poses significant risks to consumers, including severe health complications such as facial necrosis or disfigurement [2][42]. - Cases have emerged where consumers received injections of unverified products, leading to complaints and potential legal issues for medical institutions [27][29][38]. - The article warns that if incidents of health risks continue, consumer trust in legitimate medical aesthetics channels may collapse, undermining the industry's credibility [43]. Group 4: Business Strategies - Medical institutions are increasingly adopting the private label model to gain pricing power and differentiate themselves in a saturated market, often branding these products as exclusive or specially developed [14][40]. - The strategy of using legitimate products for marketing while substituting them with private label versions is referred to as "cat swapping," reflecting a deceptive practice that could harm consumer safety [40][41]. - The article suggests that the current business model driven by high profits and regulatory gaps may not be sustainable in the long term, urging companies to focus on brand integrity and consumer safety [44].

Core Viewpoint - The article highlights the opening event of the Baidachu Aesthetic Medicine Concept Verification Center, emphasizing its role as a pioneering platform in China for the transformation of plastic surgery technology achievements [6]. Group 1: Event Details - The event is scheduled for June 27, 2025, from 14:00 to 16:00 at the Langcheng Building in Beijing [4]. - The expected scale of the event is around 20 participants, including medical aesthetic entrepreneurs, investors, and industry professionals [4]. - The agenda includes a center introduction, self-introductions, and a session for free communication [4][6]. Group 2: Center Overview - The Baidachu Aesthetic Medicine Concept Verification Center is the first specialized platform in China focusing on the transformation of plastic surgery scientific achievements [6]. - The center relies on the Chinese Academy of Medical Sciences Plastic Surgery Hospital and focuses on innovations related to materials, instruments, and drug-device combinations [6]. - It aims to provide support and collaboration networks for doctors, enterprises, and research teams from concept to product [6].

环球市场动态 内 地 财 政 对 资 金 面 压 力 将 明 显 增 加 股 票 以色列伊朗停战，全球股市情绪大 幅反弹。A 股上涨，沪指重回 3400 店；港股全线上涨，权重的科技股、 金融股纷纷走高；欧洲交易时段尽 管以色列和伊朗双方都指责对方破 坏停火协议，但市场乐观情绪仍较 高推动强劲收涨；鲍威尔国会证词 提及降息，美股三大指数均涨超 1%，金龙中国指数涨 3%。 外 汇 / 商 品 以伊停火协议缓解供应担忧，并且 特朗普表示中国可以继续购买伊朗 石油，原油价格连续第二天重挫； 中东局势降温减弱避险需求，周二 国际金价下跌近 2%；美国消费者 信心弱于预期，鲍威尔降息前景发 出偏平衡的信号，美元指数下跌 0.6%至 97.86。 固 定 收 益 美国短期国债领涨；地缘政治局势 缓和；美国消费者信心意外下降； 鲍威尔重申观望立场，未排除 7 月 降息可能；两年期美债拍卖中标利 率略低于发行前水平，需求略显平 淡。亚洲债市情绪改善，中国投资 级债券利差收窄 1-3bp。 产品及投资方案部 注：bp/bps=基点；pt/pts=百分点 中信证券财富管理 (香港) 免责声明请参考封底 2025 年 6 月 2 ...

Group 1 - The recent tensions in the Middle East have led to a temporary impact on A-share market sentiment, but the market has rebounded, with the Shanghai Composite Index reaching a new high in nearly a month [1] - The market is expected to maintain a slow upward trend as it approaches the policy window period at the end of June, with potential for new policies aimed at stabilizing employment and promoting high-quality development [1] - Popular sectors such as banking and innovative pharmaceuticals may experience short-term fluctuations due to accumulated gains, while TMT and technology growth sectors are anticipated to see a rebound after sufficient adjustments [1] Group 2 - The outlook for July suggests a theme-driven market with high-low sector rotation, as popular sectors like innovative pharmaceuticals and banking have shown signs of correction, while TMT and advanced manufacturing sectors are beginning to rebound [2] - Key focus areas for 2025 include expanding domestic demand and consumption, with expectations for policies to support sectors like dairy products, IP consumption, leisure tourism, and medical aesthetics [2] - The trend towards domestic production of robotics is expected to continue, with opportunities arising in sensors, controllers, and functional robots [2] - The semiconductor industry is projected to see continued domestic growth, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The military industry is anticipated to experience a rebound in orders by 2025, with signs of recovery already visible in various sub-sectors [2] - The innovative pharmaceutical sector is expected to reach a turning point in fundamentals by 2025, following a period of adjustment [2] - The AI sector is poised for new catalysts, with significant updates expected from companies like MiniMax, indicating a resurgence in AI-related investments [2] Group 3 - The A-share market has ended a month-long period of consolidation, with the Shanghai Composite Index reaching a new high, supported by a broad-based rally among individual stocks [3] - The market saw a significant increase in the number of rising stocks, with over 4,700 stocks gaining, while only a few sectors like oil and coal experienced declines due to falling international oil prices [3] - Leading sectors included electric power equipment, non-bank financials, retail, automotive, and machinery [3]